ASM 8

Drug Profile

ASM 8

Alternative Names: ASM8; TPI-ASM8

Latest Information Update: 10 Aug 2015

Price : $50

At a glance

  • Originator Topigen Pharmaceuticals
  • Developer Pharmaxis
  • Class Anti-inflammatories; Antiasthmatics; Antisense oligonucleotides
  • Mechanism of Action CCR3 receptor antagonists; Granulocyte macrophage colony stimulating factor antagonists; Interleukin 3 receptor antagonists; Interleukin 5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Allergic asthma; Asthma

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 10 Aug 2015 No recent reports on development identified - Phase-II for Allergic asthma in Canada (Inhalation)
  • 10 Aug 2015 No recent reports on development identified - Phase-II for Asthma in United Kingdom (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top